Real-time quantitative RT-PCR identifies distinct c-RET, RET/PTC1 and RET/PTC3 expression patterns in papillary thyroid carcinoma
- PMID: 15502856
- DOI: 10.1038/labinvest.3700198
Real-time quantitative RT-PCR identifies distinct c-RET, RET/PTC1 and RET/PTC3 expression patterns in papillary thyroid carcinoma
Abstract
RET/PTC1 and RET/PTC3 are the markers for papillary thyroid carcinoma. Their reported prevalence varies broadly. Nonrearranged c-RET has also been detected in a variable proportion of papillary carcinomas. The published data suggest that a wide range in expression levels may contribute to the different frequency of c-RET and, particularly, of RET/PTC detection. However, quantitative expression analysis has never been systematically carried out. We have analyzed by real-time RT-PCR 25 papillary carcinoma and 12 normal thyroid samples for RET/PTC1, RET/PTC3 and for RET exons 10-11 and 12-13, which are adjacent to the rearrangement site. The variability in mRNA levels was marked and four carcinoma groups were identified: one lacking RET/PTC rearrangement with balanced RET exon levels similar to those of the normal samples (7/25 cases, 28%), the second (6/25 cases, 24%) with balanced RET expression and very low levels of RET/PTC1, the third with unbalanced RET exons 10-11 and 12-13 expression, high RET/PTC1 levels but no RET/PTC3 (7/25 cases, 28%), and the fourth with unbalanced RET expression, high RET/PTC1 levels and low levels of RET/PTC3 (5/25 cases, 20%). Papillary carcinomas with high RET/PTC1 expression showed an association trend for large tumor size (P=0.063). Our results indicate that the variability in c-RET and RET/PTC mRNA levels contributes to the apparent inconsistencies in their reported detection rates and should be taken into account not only for diagnostic purposes but also to better understand the role of c-RET activation in thyroid tumorigenesis.
Similar articles
-
Low prevalence of RET rearrangements (RET/PTC1, RET/PTC2, RET/PTC3, and ELKS-RET) in sporadic papillary thyroid carcinomas in Taiwan Chinese.Thyroid. 2005 Apr;15(4):326-35. doi: 10.1089/thy.2005.15.326. Thyroid. 2005. PMID: 15876154
-
RET/PTC rearrangements in thyroid nodules: studies in irradiated and not irradiated, malignant and benign thyroid lesions in children and adults.J Clin Endocrinol Metab. 2001 Jul;86(7):3211-6. doi: 10.1210/jcem.86.7.7678. J Clin Endocrinol Metab. 2001. PMID: 11443191
-
Papillary thyroid carcinoma: 6 cases from 2 families with associated lymphocytic thyroiditis harbouring RET/PTC rearrangements.Br J Cancer. 2001 Dec 14;85(12):1831-7. doi: 10.1054/bjoc.2001.2187. Br J Cancer. 2001. PMID: 11747322 Free PMC article.
-
RET/PTC rearrangement in thyroid tumors.Endocr Pathol. 2002 Spring;13(1):3-16. doi: 10.1385/ep:13:1:03. Endocr Pathol. 2002. PMID: 12114746 Review.
-
[Rearrangement of the RET gene in papillary thyroid carcinoma].Wiad Lek. 2001;54 Suppl 1:64-71. Wiad Lek. 2001. PMID: 12182064 Review. Polish.
Cited by
-
A study to evaluate association of nuclear grooving in benign thyroid lesions with RET/PTC1 and RET/PTC3 gene translocation.Thyroid Res. 2023 Jul 3;16(1):21. doi: 10.1186/s13044-023-00161-9. Thyroid Res. 2023. PMID: 37394464 Free PMC article.
-
RET rearrangements are relevant to histopathologic subtypes and clinicopathological features in Thai papillary thyroid carcinoma patients.Pathol Oncol Res. 2023 Apr 28;29:1611138. doi: 10.3389/pore.2023.1611138. eCollection 2023. Pathol Oncol Res. 2023. PMID: 37188126 Free PMC article.
-
Expanding the Spectrum of BRAF Non-V600E Mutations in Thyroid Nodules: Evidence-Based Data from a Tertiary Referral Centre.Int J Mol Sci. 2023 Feb 17;24(4):4057. doi: 10.3390/ijms24044057. Int J Mol Sci. 2023. PMID: 36835466 Free PMC article.
-
Case report: Dramatic response to pralsetinib in an elderly patient with advanced RET-fusion positive papillary thyroid carcinoma.Front Oncol. 2022 Dec 12;12:1042525. doi: 10.3389/fonc.2022.1042525. eCollection 2022. Front Oncol. 2022. PMID: 36578928 Free PMC article.
-
RET signaling pathway and RET inhibitors in human cancer.Front Oncol. 2022 Jul 25;12:932353. doi: 10.3389/fonc.2022.932353. eCollection 2022. Front Oncol. 2022. PMID: 35957881 Free PMC article. Review.
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Medical
